Clave de Autorización: 0009300201A22345
Welcome To Taj Pharmaceuticals Ltd API |
About Worldwide | FAQs | Careers | | Media Center | | Taj Pharmaceuticals World | | TAJ Group |
|||||
|
||||||
India Latin America/ Caribbean Africa & Middle East Asia Russia Europe | ||||||
|
|
HOME >> API >> API List1 >> Acamprosate Calcium >> Acamprosate Calcium Pharmacology
PharmacologyChronic alcohol exposure may alter normal balance between neuronal and excitation and inhibition. In vitro and in vivo animal data suggest acamprosate interacts with glutamate and GABA neurotransmitter systems, restoring this balance. PharmacokineticsAbsorptionBioavailability about 11%. Steady state reached within 5 days. Steady-state concentrations average 350 ng/mL and occur 3 to 8 h postdose. C max and AUC approximately 42% and 23%, respectively. DistributionVd estimated to be 72 to 109 L (1 L/kg). Protein binding is negligible. MetabolismDoes not undergo metabolism. EliminationTerminal t ˝ ranges from about 20 to 33 h. Major route of excretion is via kidneys. Special PopulationsRenal function impairment C max in patients with moderate or severe renal function impairment were 2- and 4-fold higher, respectively. Elimination t ˝ were 1.8- and 2.6-fold longer, respectively. Indications and UsageMaintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. ContraindicationsSevere renal function impairment (Ccr 30 mL/min or less); hypersensitivity to any component of product. Dosage and AdministrationAdults PO Two 333 mg tablets 3 times daily. Renal Function Impairment PO Start with 333 mg 3 times daily in patients with moderate renal function impairment (Ccr 30 to 50 mL/min). Do not administer to patients with severe renal function impairment (Ccr 30 mL/min or less). Storage/StabilityStore tablets at controlled room temperature (59° to 86°F).
|
|
---|
Investor Relations Feedback Contact Worldwide Sitemap | |